key: cord-0906971-ct1y9amm
authors: Li, Yubin
title: Human neutralizing antibodies to SARS-CoV-2: views and perspectives from Professor Linqi Zhang at Tsinghua University
date: 2020-06-06
journal: Antib Ther
DOI: 10.1093/abt/tbaa013
sha: a238c69b43644a62be7a4253356d40e2881bc90f
doc_id: 906971
cord_uid: ct1y9amm

Professor Linqi Zhang’s laboratory has uncovered the structure of SARS-CoV-2 spike receptor-binding domain binding with cell receptor angiotensin converting enzyme 2, and isolated more than 200 receptor-binding domain-specific monoclonal antibodies against SARS-CoV-2. The top SARS-CoV-2 neutralizing antibodies are now under development with partnership in pharmaceutical industry.

neutralizing antibodies targeting SARS-CoV-2 at early preclinical stages [3, 4] .

As an enveloped single strand RNA virus, SARS-CoV-2 enters into cells through its spike (S) protein binding to the cell receptor angiotensin converting enzyme 2 (ACE2). In order to discover and develop effective neutralizing antibodies to SARS-CoV-2, the structure of the SARS-CoV-2 spike receptor-binding domain (RBD) bound to ACE2 is very important [5] . This crystal structure was firstly published in [3] Biopharma products in development for COVID-19.

Update: Public Health Response to the Coronavirus Disease

Outbreak -United States

Antibody therapies for the treatment of COVID-19

Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Human antibodies can neutralize SARS-CoV-2

The author would like to thank Mitchell Ho, Shouye Wang, Songyu Wang, and Sisi Shan for reading and editing the manuscript. The author declares no conflict of interest.